Hengrui Pharmaceuticals

Hengrui Pharmaceuticals (stock code: 600276.SH, 01276.HK) was founded in 1970 and listed on the Shanghai Stock Exchange in 2000 and on the Hong Kong Stock Exchange in 2025, becoming an "A+H" dual-listed company. As an innovative international pharmaceutical enterprise dedicated to the research, development, production, and promotion of high-quality drugs, Hengrui has adhered to its original commitment of "patient-centeredness" throughout over 50 years of development. Focused on areas such as oncology, metabolic and cardiovascular diseases, immunology and respiratory diseases, and neuroscience, we persistently advance drug discovery. To conquer diseases, improve quality of life, and extend lifespan, we continuously expand the boundaries of possibility, committing to leverage the power of technology to benefit patients worldwide.

Hengrui Pharmaceuticals has been ranked among the top 50 global pharmaceutical companies by the US-based PharmExec magazine for 7 consecutive years. Additionally, according to the global TOP25 pipeline scale ranking published by the internationally renowned consulting firm Citeline, Hengrui has been listed for 4 consecutive years, ranking second globally in the number of self-developed pipeline drugs.

Safeguarding health with innovation - Hengrui Pharmaceuticals consistently prioritizes technological innovation as its primary development strategy and continues to increase R&D investment. To date, the company's cumulative R&D investment has exceeded RMB 50 billion, ranking among the top in the national pharmaceutical industry. Hengrui has established 15 R&D centers across China, Japan, the United States, Australia, and Switzerland, with a global R&D team of over 5,600 personnel. R&D investment has yielded fruitful innovation outcomes: 24 Class 1 innovative drugs and 5 Class 2 new drugs have been approved for marketing in China, over 100 self-developed innovative products are in clinical development, and more than 400 clinical trials are being conducted domestically and internationally. This forms a virtuous cycle of launching products, advancing clinical trials, and developing pipeline drugs. The company has also independently established cutting-edge technology platforms, including proteolysis-targeting chimeras (PROTAC), peptide drugs, monoclonal antibodies, bispecific antibodies, multispecific antibodies, antibody-drug conjugates (ADC), and radioligand therapy, and is continuously expanding platforms such as AI-driven drug discovery, providing a strong foundation for innovative R&D.

Driving Chinese pharmaceutical brands to the world - Steadily advancing internationalization is a long-term development strategy for Hengrui Pharmaceuticals. Currently, the company's products have entered over 40 countries and regions, while continuing to expedite global market expansion with a focus on emerging markets. The company emphasizes both independent R&D and open collaboration, strengthening international partnerships on the basis of internal growth. Since 2020, Hengrui has executed 15 out-licensing transactions with global partners, with a potential total value exceeding USD 27 billion, and has also acquired equity stakes in certain partners. Additionally, the company has initiated over 20 international clinical trials for innovative drugs. Moreover, Hengrui has obtained more than 20 registration approvals in Europe, the United States, and Japan, including injectables, oral formulations, and inhaled anesthetics, thereby enhancing drug accessibility for patients in various regions worldwide.

In the future, we will steadfastly uphold our mission of "science and technology as the foundation, promoting healthy lives for humanity" and our vision of "focusing on innovation to build a multinational pharmaceutical group," striving to develop more new, high-quality drugs and serving human health through technological innovation.